ReviewNeuroscience and biobehavioral reviews2024
Exploring causal mechanisms of psychosis risk.
Review in Neuroscience and biobehavioral reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- The cross-site reproducibility of MRI morphometric phenotypes in psychiatric disorders.Nature neuroscience · 2026Article
- Cannabis use and glutamate across the psychosis spectrum: in vivo evidence from 7T proton magnetic resonance spectroscopy.Molecular psychiatry · 2026Article
- clickBrick prompt engineering: optimizing large language model performance in clinical psychiatry.Npj mental health research · 2026Article
- Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Generalizability of findings from neurobiological studies of individuals with first-episode psychosis: a cohort study.Schizophrenia (Heidelberg, Germany) · 2026Article
- Lineage specification into GABAergic, glutamatergic, dopaminergic, and astrocytic phenotypes using MUSE stem cells: a novel approach for modeling neurodegenerative and psychiatric disorders.Molecular psychiatry · 2026Article
- Searching for people with psychosis in the global south: mapping and establishing a case surveillance system in South Africa (PSYMAP-ZN study).Social psychiatry and psychiatric epidemiology · 2026Article
- Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis.Frontiers in psychiatry · 2026Article
- Evaluating the Exposome Score for Schizophrenia in a Transdiagnostic Psychosis Cohort: Associations With Psychosis Risk, Symptom Severity, and Personality Traits.Schizophrenia bulletin · 2025Observational
- Potential risk factors for methamphetamine use among inmates in a Japanese prison.BMC psychiatry · 2025Article
- Article
- PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.Schizophrenia (Heidelberg, Germany) · 2025Article
- Clinical and functional outcomes at 7-year follow-up of children presenting putative antecedents of schizophrenia at age 9-12 years.Schizophrenia (Heidelberg, Germany) · 2024Article
- Exploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robust epidemiological evidence of risk and protective factors for psychosis is essential to inform preventive interventions. Previous evidence syntheses have classified these risk and protective factors according to their strength of association with psychosis. In this critical review we appraise the distinct and overlapping mechanisms of 25 key environmental risk factors for psychosis, and link these to mechanistic pathways that may contribute to neurochemical alterations hypothesised to underlie psychotic symptoms. We then discuss the implications of our findings for future research, specifically considering interactions between factors, exploring universal and subgroup-specific factors, improving understanding of temporality and risk dynamics, standardising operationalisation and measurement of risk and protective factors, and developing preventive interventions targeting risk and protective factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.